Please login to the form below

Halaven

This page shows the latest Halaven news and features for those working in and with pharma, biotech and healthcare.

NICE set to reject wider use of Eisai’s Halaven

Issues draft guidance recommending against second-line use in breast cancer. Eisai’s Halaven (eribulin) should not be funded by the NHS for earlier use in breast cancer patients, according to ... NICE agreed last year that Halaven should be made

Latest news

NICE backs Eisai's Halaven for breast cancer

NICE has given a green light to Eisai's third-line breast cancer therapy Halaven, reversing its 2012 rejection of the drug. ... Halaven is one of Eisai's key growth products, accounting for 18.6bn yen ($181m) in sales in the first half of this fiscal year
Lilly closes on first approval for sarcoma drug Lartruvo

If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved
Eisai gets green light for Lenvima in kidney cancer

Earlier this month, Eisai won EU approval for its Halaven (eribulin mesylate) product as a second-line treatment for adults with inoperable advanced liposarcoma, its second indication after metastatic breast cancer.
Oncology directions

Halaven (eribulin).
Disappointment for pharma with new Cancer Drugs Fund list

While Bayer has seen reprieve the rest were not so lucky, with Eisai's breast cancer drug Halaven (eribulin), Lilly's lung cancer therapy Alimta (pemetrexed) and Roche's blockbuster

More from news
Approximately 8 fully matching, plus 18 partially matching documents found.

Latest Intelligence

Eisai: Bucking the trend with R&D growth

The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets. ... Halaven's unique position as the only drug demonstrating overall survival benefit in patients who are
Country report: The healthcare market in Japan

The approval of Halaven (eribulin, Eisai) for progressive breast cancer in the US in late 2010, and in Europe and Japan in early 2011, signalled the impact of a growing number

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Account Management: Competitive Salary Offered

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Principal Medical Writer: Varies on experience

PMHub

Add my company

Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...